Strategic Approaches for Developing Alternative Tests for Safety and Potency of Vaccines

Procedia in Vaccinology

Volumn 5, Issue , 2011, Pages 156-163

  Horiuchi, Yoshinobu ^a,b   Ochiai, Masaki ^a   Kataoka, Michiyo ^a   Yamamoto, Akihiko ^a   Yuen, Chun Ting ^c   Asokanathan, Cathy ^c   Corbel, Michael ^c   Kurata, Takeshi ^a   Xing, Dorothy ^c  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b PHARMACEUTICALS AND MEDICAL DEVICES AGENCY   (Japan)

^c NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

Alternative methods; Human vaccines; Vaccine potency testing; Vaccine safety testing

Indexed keywords

CELL SURFACE RECEPTOR; ENDOTOXIN; HISTAMINE; PERTUSSIS TOXIN; PERTUSSIS VACCINE;

ARTICLE; CELL ACTIVATION; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; ENDOTOXIN DETECTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOGENICITY; IN VITRO STUDY; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; SENSITIZATION;

EID: 84555196676     PISSN: None     EISSN: 1877282X     Source Type: Journal    
DOI: 10.1016/j.provac.2011.10.014     Document Type: Article

References (28)

1. Yamamoto A, Nagata N, Ochiai M, Kataoka M, Toyoizumi H, Okada K, Horiuchi Y. Enhanced sensitisation of mice with diphtheria tetanus acellular pertussis vaccine to local swelling reaction to the booster immunisation. Vaccine 2002 Aug 19;20(25-26):3088-94.
2. Michael S Gold, Sara Noonan, Maggi Osbourn, Stella Precepa and Ann E Kempe. Local reactions after the fourth-dose of acellular pertussis vaccine in South Australia. MJA 2003;179: 91-194.
3. NOTE FPR GUIDANCE ON PRECLINICAL AND TOXICOLOGICAL TESTING OF VACCINES CPMP/SWP/465/95.
4. Michiyo Kataoka,Akihiko Yamamoto, Masaki Ochiai, Ayako Harashima, Noriyo Nagata, Hideki Hasegawa, Takeshi Kurata, Yoshinobu Horiuchi. Comparison of acellular pertussis-based combination vaccines by Japanese control tests for toxicities and laboratory models for local reaction. Vaccine 2009;27:1881-1888.
5. Arciniega J. L., Corbel M., Dellepiane N., Dobbelaer R., Griffiths E., Heron I., Ivanoff B., Kreeftenberg H., Mastrantonio P., Meade B., Milstein J., Robertson S., Robinson A., Sato H., Sato Y., Schwanig M., Tiru M. WHO guidelines for the production and control of the acellular pertussis component of monovalent or combined vaccines. Biologicals 1998;26:195-204.
6. Kreeftenberg J. G. Standardization of acellular pertussis vaccines. Biologicals 1999;27:115-117.
7. Yamamoto A, Ochiai M, Fujiwara H, Asakawa S, Ichinohe K, Kataoka M, Toyoizumi H, Horiuchi Y. Evaluation of the applicability of the bacterial endotoxin test to antibiotic products. Biologicals 2000 Sep;28(3):155-67.
8. Ochiai M, Yamamoto A, Naito S, Maeyama J, Masumi A, Hamaguchi I, Horiuchi Y, Yamaguchi K Applicability of bacterial endotoxins test to various blood products by the use of endotoxin-specific lysates. Biologicals 2010 Nov;38(6):629-36.
9. MINIMUM REQUIREMENTS FOR BIOLOGICAL PRODUCTS, http://www.nih.go.jp/niid/MRBP/files/seibutsuki_english.pdf.
10. Ochiai M, Kataoka M, Toyoizumi H, Yamamoto A, Kamachi K, Horiuchi Y. A quantitative in vitro assay method for detecting biological activity of endotoxin using prostaglandin E2 induction in rabbit peripheral blood. Microbiol Immunol. 2003; 47(8):585-90, Japanese.
11. Yamamoto A, Sakai T, Ochiai M, Kamachi K, Kataoka M, Toyoizumi H, Horiuchi Y. A cell line assay system for predicting the response of human blood to endotoxin. Jpn J Infect Dis 2003 Jun;56(3):93-100.
12. Iwasa S., Ishida S., Asakawa S., Akama K. A curious histamine-sensitizing activity shown by the newly-developed Japanese acellular pertussis vaccine. Dev Biol Stand 1985;61:453-60.
13. Parfentjev, I.A. and Goodline, M.A.: Histamine shock in mice sensitized with Hemophilus pertussis vaccine. J Pharm Exp Ther 1948;92:411-413.
14. Ishida S., Kurokawa M., Asakawa S., Iwasa S. A sensitive assay method for the histamine-sensitizing factor using change in rectal temperature of mice after histamine challenge as a response. J Biol Stand 1979;7:21-9.
15. Ochiai M, Yamamoto A, Kataoka M, Toyoizumi H, Arakawa Y, Horiuchi Y., Highly sensitive histamine-sensitization test for residual activity of pertussis toxin in acellular pertussis vaccine. Biologicals 2007 Oct;35(4):259-64.
16. Kataoka M, Toyoizumi H, Yamamoto A, Ochiai M, Horiuchi Y. Chinese hamster ovary (CHO) cell clustering does not correlate with in vivo histamine-sensitization when measuring residual activity of aldehyde-treated pertussis toxin (PT). Biologicals 2002 Dec;30(4):297-302.
17. Chun-Ting Yuena, Yoshinobu Horiuchib, Catpagavalli Asokanathana, Sarah Cooka, Alexandra Douglas-Bardsleya, Masaki Ochiaic, Michael Corbela,Dorothy Xinga, An in vitro assay system as a potential replacement for the histamine sensitisation test for acellular pertussis based combination vaccines. Vaccine 2010;28:3714-3721.
18. Schmidt, M.A., B. Raupach, M. Szulczynski, and J. Marzillier. 1991. Identification of linear B-cell determinants of pertussis toxin associated with the receptor recognition site of the S3 subunit. Infect. Immun. 59:1402-1408.
19. April TALLETT, Richard N. SEABROOK, Laurence I. IRONS, Andrew ROBINSON, Simon VAN HEYNINGEN, Tony ATKINSON, Localisation of a receptor-recognition domain on the S3 subunit of pertussis toxin by peptide mapping. European Journal of Biochemistry, Volume 211, Issue 3, pages 743-748, February 1993.
20. Schmidt, W., and M. A. Schmidt. 1989. Mapping of linear B-cell epitopes of the S2 subunit of pertussis toxin. Infect. Immun. 57:438 445.
21. British Medical Research Council. Vaccination against whooping cough: Correlation between protection in children and results of laboratory tests. BMJ 1956;2:454-462.
22. Standfast A. F. B. The comparison between field trials and mouse protection tests against intranasal and intracerebral challenges with Bordetella pertussis. Immunology 1959;2:135-143.
23. Olin P. The Swedish efficacy trial of acellular pertussis vaccines--update and time for reflection. Dev Biol Stand 1991;73:33-36.
24. Sato Y., Arai H., Suzuki K. Leukocytosis-promoting factor of Bordetella pertussis III. Its identity with protective antigen. Infect Immun 1974;9:801-810.
25. Robinson A., Ashworth L. A., Baskerville A., Irons L. I. Protection against intranasal infection of mice with Bordetella pertussis. Dev Biol Stand 1985;61:165-172.
26. Sato Y., Kimura M., Fukumi H. Development of a pertussis component vaccine in Japan. Lancet 1984; 323 Issue 8369:122-126.
27. Arno van der Arka, Ineke van Straaten-van de Kappelle, Rose-Marie ölander, Karlheinz Enssle, Suresh Jadhav, Huib van de Donk and Coenraad Hendriksen The Pertussis Serological Potency Test Collaborative Study to Evaluate Replacement of the Mouse Protection Test. Biologicals 2000;28(2):105-118.
28. Hendriksen C, Winsnes R. Serological methods for potency testing of tetanus toxoid vaccines for human use. Dev Biol (Basel) 2002;111:131-40.